Opinion statement Poly-ADP-ribose polymerase inhibitors (PARPi) are a class of anti-cancer
drugs that target DNA repair pathways and have shown promising efficacy in patients with …

Purpose: We hypothesized that inhibition and trapping of PARP1 alone would be sufficient
to achieve antitumor activity. In particular, we aimed to achieve selectivity over PARP2 …

Abstract Poly (ADP‐ribose) polymerase 1 (PARP1) is a key mediator of various forms of
DNA damage repair and plays an important role in the progression of several cancer types …

Aims The aim of this study was to determine the differences and potential mechanistic
rationale for observed adverse drug reactions (ADRs) between four approved PARP …

Purpose: We evaluated the properties and activity of AZD9574, a blood–brain barrier (BBB)
penetrant selective inhibitor of PARP1, and assessed its efficacy and safety alone and in …

As the first FDA-approved PARP1/2 inhibitor, olaparib (OLA) is a blockbuster anticancer
drug, but its use has been limited by the dose-limiting toxicity and short half life of …

Skin cancers, including basal cell carcinoma (BCC), cutaneous squamous cell carcinoma
(SCC), and melanoma, are the most common malignancies in the United States. Loss of …

Simple Summary PARP inhibitors are a class of orally active drugs that kill a range of cancer
types by inducing synthetic lethality. The usefulness of PARP inhibitors for the treatment of …

Designing selective PARP-1 inhibitors has become a new strategy for anticancer drug
development. By sequence comparison of PARP-1 and PARP-2, we identified a possible …

Poly (adenosine diphosphate [ADP]–ribose) polymerases inhibitors (PARPi), the first
clinically approved drug that exhibits synthetic lethality, are moving to the forefront of cancer …